ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharitis
Conditions
Blepharitis
Trial Timeline
Oct 1, 2011 → Jun 1, 2013
NCT ID
NCT01408082About ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone is a phase 3 stage product being developed by Sun Pharmaceutical for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01408082. Target conditions include Blepharitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01408082 | Phase 3 | Completed |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 80 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 72 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 60 |
| Lotilaner + Vehicle Control | LianBio | Phase 3 | 69 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| Azithromycin ophthalmic solution, 1% + Vehicle | Merck | Phase 2 | 52 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 74 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 49 |
| KPI-121 + Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85